161 related articles for article (PubMed ID: 2690972)
1. Megestrol acetate versus aminoglutethimide for metastatic breast cancer.
Lundgren S; Gundersen S; Klepp R; Lønning PE; Lund E; Kvinnsland S
Breast Cancer Res Treat; 1989 Nov; 14(2):201-6. PubMed ID: 2690972
[TBL] [Abstract][Full Text] [Related]
2. Megestrol acetate in advanced breast carcinoma after failure to tamoxifen and/or aminoglutethimide.
Brufman G; Isacson R; Haim N; Gez E; Sulkes A
Oncology; 1994; 51(3):258-61. PubMed ID: 8196908
[TBL] [Abstract][Full Text] [Related]
3. Randomized trial of tamoxifen versus tamoxifen plus aminoglutethimide as adjuvant treatment in postmenopausal breast cancer patients with hormone receptor-positive disease: Austrian breast and colorectal cancer study group trial 6.
Schmid M; Jakesz R; Samonigg H; Kubista E; Gnant M; Menzel C; Seifert M; Haider K; Taucher S; Mlineritsch B; Steindorfer P; Kwasny W; Stierer M; Tausch C; Fridrik M; Wette V; Steger G; Hausmaninger H
J Clin Oncol; 2003 Mar; 21(6):984-90. PubMed ID: 12637461
[TBL] [Abstract][Full Text] [Related]
4. Megestrol acetate and aminoglutethimide/hydrocortisone in sequence or in combination as second-line endocrine therapy of estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group phase III trial.
Russell CA; Green SJ; O'Sullivan J; Hynes HE; Budd GT; Congdon JE; Martino S; Osborne CK
J Clin Oncol; 1997 Jul; 15(7):2494-501. PubMed ID: 9215817
[TBL] [Abstract][Full Text] [Related]
5. [Progestational agents and bone metastasis in breast cancer].
Leriche N; Bonneterre J
Bull Cancer; 1997 Sep; 84(9):891-4. PubMed ID: 9435812
[TBL] [Abstract][Full Text] [Related]
6. Oestrogen receptors and the response of metastatic breast cancer to aminoglutethimide or tamoxifen.
Holdaway IM
Aust N Z J Surg; 1981 Aug; 51(4):345-7. PubMed ID: 6944051
[TBL] [Abstract][Full Text] [Related]
7. Randomized trial of aminoglutethimide versus tamoxifen in metastatic breast cancer.
Lipton A; Harvey HA; Santen RJ; Boucher A; White D; Bernath A; Dixon R; Richards G; Shafik A
Cancer Res; 1982 Aug; 42(8 Suppl):3434s-3436s. PubMed ID: 7044526
[TBL] [Abstract][Full Text] [Related]
8. Aminoglutethimide in advanced breast cancer.
Ceci G; Passalacqua R; Bisagni G; Bella M; Cocconi G
Tumori; 1985 Oct; 71(5):483-9. PubMed ID: 2865833
[TBL] [Abstract][Full Text] [Related]
9. Use of aminoglutethimide as second-line endocrine therapy in metastatic breast cancer.
Kaye SB; Woods RL; Fox RM; Coates AS; Tattersall MH
Cancer Res; 1982 Aug; 42(8 Suppl):3445s-3447s. PubMed ID: 6177404
[TBL] [Abstract][Full Text] [Related]
10. Megestrol acetate v tamoxifen in advanced breast cancer in postmenopausal patients.
Morgan LR
Semin Oncol; 1985 Mar; 12(1 Suppl 1):43-7. PubMed ID: 3975652
[TBL] [Abstract][Full Text] [Related]
11. Randomized comparison of the effects of tamoxifen, megestrol acetate, or tamoxifen plus megestrol acetate on treatment response and survival in patients with metastatic breast cancer.
Gill PG; Gebski V; Snyder R; Burns I; Levi J; Byrne M; Coates A
Ann Oncol; 1993 Nov; 4(9):741-4. PubMed ID: 8280654
[TBL] [Abstract][Full Text] [Related]
12. Aminoglutethimide as second line endocrine therapy in advanced breast cancer.
Brufman G; Biran S
Anticancer Res; 1986; 6(5):1065-8. PubMed ID: 3800315
[TBL] [Abstract][Full Text] [Related]
13. Quantitative estrogen and progesterone receptor levels related to progression-free interval in advanced breast cancer patients treated with megestrol acetate or tamoxifen.
Bonomi P; Gale M; Von Roenn J; Anderson K; Johnson P; Wolter J; Economou S
Semin Oncol; 1988 Apr; 15(2 Suppl 1):26-33. PubMed ID: 3368797
[TBL] [Abstract][Full Text] [Related]
14. Second line hormonal therapy with aminoglutethimide in metastatic breast cancer.
Brufman G; Biran S
Acta Oncol; 1990; 29(6):717-20. PubMed ID: 2223141
[TBL] [Abstract][Full Text] [Related]
15. Megestrol acetate therapy for advanced breast cancer.
Gregory EJ; Cohen SC; Oines DW; Mims CH
J Clin Oncol; 1985 Feb; 3(2):155-60. PubMed ID: 3838187
[TBL] [Abstract][Full Text] [Related]
16. Tamoxifen versus aminoglutethimide in advanced breast carcinoma: a randomized cross-over trial.
Smith IE; Harris AL; Morgan M; Ford HT; Gazet JC; Harmer CL; White H; Parsons CA; Villardo A; Walsh G; McKinna JA
Br Med J (Clin Res Ed); 1981 Nov; 283(6304):1432-4. PubMed ID: 6797571
[TBL] [Abstract][Full Text] [Related]
17. A randomized trial on tamoxifen continuation during second-line hormone therapy in breast cancer.
Pronzato P; Bertelli G; Rosso M
Ann N Y Acad Sci; 1993 Nov; 698():357-61. PubMed ID: 8279775
[No Abstract] [Full Text] [Related]
18. Aminoglutethimide without hydrocortisone in the treatment of postmenopausal patients with advanced breast cancer.
Höffken K; Kempf H; Miller AA; Miller B; Schmidt CG; Faber P; Kley HK
Cancer Treat Rep; 1986 Oct; 70(10):1153-7. PubMed ID: 3756937
[TBL] [Abstract][Full Text] [Related]
19. A phase II evaluation of combination chemotherapy plus aminoglutethimide in women with metastatic or recurrent breast carcinoma. An Eastern Cooperative Oncology Group Pilot Study.
Grem JL; Falkson G; Love RR; Tormey DC
Am J Clin Oncol; 1988 Oct; 11(5):528-34. PubMed ID: 3177253
[TBL] [Abstract][Full Text] [Related]
20. Aminoglutethimide in patients with metastatic breast cancer.
Nemoto T; Rosner D; Patel JK; Dao TL
Cancer; 1989 May; 63(9):1673-5. PubMed ID: 2467735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
